CCL2 and hematocrit: Notably, Treg therapy appears to be able to exert an additional protective effect in CCL2 knockout mice, maintaining BBB integrity and reducing the risk of tPA-induced HT after AIS through Tregs-dependent dual inhibition of MMP-9 and CCL2 [130].